Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis

Inclusion Criteria:

- Men or women (not nursing or pregnant) over 18 years old who have active RA, defined
as symptoms of RA prior to screening and have satisfied the ACR/EULAR 2010 criteria
for the classification of RA prior to signing the informed consent.

- Subjects must have a DAS28CRP and CDAI assessment at screening and have at least 3
tender and at least 3 swollen joints (excluding distal interphalangeal joints) at
screening and at Day 1. Patients must have at least moderate disease activity
{CDAI>16); DAS28CRP (>4.0 )].

- Subjects must be naive to biologic DMARDs

- Subjects must be naive to targeted synthetic DMARDs such as tofacitinib, baricitinib,
and investigational therapies for RA.

- Subjects receiving oral corticosteroids must be on a stable dose and at the equivalent
of 10 mg prednisone daily for at least 4 weeks. Subjects may not receive an IM, IV or
IA administration of a corticosteroid within 4 weeks prior to screening visit or
initiation of therapy

- Patients with prior (including discontinued) therapy with Methotrexate and/or
Hydroxychloroquine are permitted as long as they meet other inclusionary criteria.

- Subjects must have a DAS28CRP and CDAI at screening and have at least 3 tender and at
least 3 swollen joints (excluding distal interphalangeal joints) at screening and at
Day 1.

Exclusion Criteria:

- Subjects with autoimmune disease other than RA [e.g., psoriasis, systemic lupus
erythematosus (SLE), vasculitis, seronegative spondyloarthritis, Inflammatory Bowel
Disease, Sjogren's syndrome] or currently active fibromyalgia.

- Prior history of or current inflammatory joint disease other than RA (such as
psoriatic arthritis, gout, reactive arthritis, Lyme disease).

Medical History and Concurrent Diseases

- Subjects who are prisoners, or compulsory detained.